<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Heart Failure Diuretic Management | EnRICH Staff Portal</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Merriweather:wght@400;700&display=swap" rel="stylesheet">
    <style>
        :root {
            --enrich-purple: #8B2A7D;
            --enrich-blue: #1E3A5F;
            --enrich-navy: #0D1B2A;
            --light-purple: #F5EBF4;
            --light-blue: #E8EEF4;
            --white: #FFFFFF;
            --text-gray: #4A5568;
            --off-white: #F8F9FA;
            --light-gray: #E9ECEF;
            --green: #006747;
            --green-light: #E6F5EF;
            --amber: #92400E;
            --amber-light: #FEF3C7;
            --amber-bg: #FFFBEB;
            --red: #991B1B;
            --red-light: #FEE2E2;
            --red-bg: #FEF2F2;
            --blue-accent: #1E40AF;
            --blue-light: #DBEAFE;
            --shadow: 0 1px 3px rgba(0,0,0,0.1), 0 1px 2px rgba(0,0,0,0.06);
            --shadow-md: 0 4px 6px rgba(0,0,0,0.07), 0 2px 4px rgba(0,0,0,0.06);
        }

        * { margin: 0; padding: 0; box-sizing: border-box; }

        body {
            font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
            background: var(--off-white);
            color: var(--enrich-navy);
            line-height: 1.6;
        }

        /* Header */
        header {
            background: linear-gradient(135deg, var(--enrich-purple) 0%, var(--enrich-blue) 100%);
            color: white;
            padding: 1rem 2rem;
            box-shadow: 0 4px 20px rgba(0,0,0,0.15);
            position: sticky;
            top: 0;
            z-index: 1000;
        }
        .header-content {
            max-width: 1200px;
            margin: 0 auto;
            display: flex;
            align-items: center;
            justify-content: space-between;
            flex-wrap: wrap;
            gap: 1rem;
        }
        .logo-section {
            display: flex;
            align-items: center;
            gap: 1rem;
            text-decoration: none;
            color: white;
        }
        .logo-section img {
            height: 50px;
            width: auto;
            background: white;
            border-radius: 8px;
            padding: 4px;
        }
        .logo-text h1 { font-size: 1.5rem; font-weight: 700; }
        .logo-text p { font-size: 0.8rem; opacity: 0.9; }
        nav { display: flex; gap: 0.5rem; flex-wrap: wrap; }
        nav a {
            background: rgba(255,255,255,0.15);
            border: 1px solid rgba(255,255,255,0.3);
            color: white;
            padding: 0.6rem 1.2rem;
            border-radius: 6px;
            font-size: 0.9rem;
            font-weight: 600;
            transition: all 0.3s ease;
            text-decoration: none;
            font-family: inherit;
        }
        nav a:hover, nav a.active { background: white; color: var(--enrich-purple); }
        nav a.pin-link { border-color: rgba(255,255,255,0.5); }
        .nhs-banner { background: var(--enrich-blue); color: white; text-align: center; padding: 0.5rem; font-size: 0.85rem; }

        /* Layout */
        main { max-width: 960px; margin: 0 auto; padding: 1.5rem; }

        .back-link {
            display: inline-block;
            color: var(--enrich-purple);
            text-decoration: none;
            font-weight: 600;
            margin-bottom: 1rem;
            font-size: 0.9rem;
        }
        .back-link:hover { text-decoration: underline; }

        /* Page Hero */
        .page-hero {
            background: linear-gradient(135deg, var(--enrich-navy) 0%, var(--enrich-blue) 100%);
            color: white;
            border-radius: 14px;
            padding: 2rem 2.5rem;
            margin-bottom: 1.5rem;
        }
        .page-hero h2 {
            font-family: 'Merriweather', Georgia, serif;
            font-size: 1.6rem;
            margin-bottom: 0.5rem;
        }
        .page-hero .subtitle { opacity: 0.85; font-size: 0.95rem; }
        .page-hero .meta {
            margin-top: 1rem;
            display: flex;
            gap: 1.5rem;
            flex-wrap: wrap;
            font-size: 0.8rem;
            opacity: 0.7;
        }

        /* Draft banner */
        .draft-banner {
            background: var(--amber-bg);
            border: 2px solid #F59E0B;
            border-radius: 10px;
            padding: 1rem 1.25rem;
            margin-bottom: 1.5rem;
            display: flex;
            align-items: flex-start;
            gap: 0.75rem;
        }
        .draft-banner .icon { font-size: 1.3rem; flex-shrink: 0; }
        .draft-banner strong { color: var(--amber); }
        .draft-banner p { color: #78350F; font-size: 0.85rem; margin: 0; }

        /* Quick Nav */
        .quick-nav {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 0.5rem;
            margin-bottom: 1.5rem;
        }
        .quick-nav a {
            background: white;
            border: 1.5px solid var(--light-gray);
            border-radius: 8px;
            padding: 0.7rem 0.75rem;
            text-decoration: none;
            color: var(--enrich-navy);
            font-size: 0.8rem;
            font-weight: 600;
            text-align: center;
            transition: all 0.2s;
            display: flex;
            align-items: center;
            justify-content: center;
            gap: 0.35rem;
        }
        .quick-nav a:hover {
            border-color: var(--enrich-purple);
            background: var(--light-purple);
            color: var(--enrich-purple);
        }

        /* Sections */
        .section {
            background: white;
            border-radius: 12px;
            box-shadow: var(--shadow);
            margin-bottom: 1.25rem;
            overflow: hidden;
        }
        .section-header {
            padding: 1rem 1.5rem;
            cursor: pointer;
            display: flex;
            align-items: center;
            justify-content: space-between;
            gap: 1rem;
            user-select: none;
            transition: background 0.2s;
        }
        .section-header:hover { background: rgba(0,0,0,0.02); }
        .section-header h3 {
            font-family: 'Merriweather', Georgia, serif;
            font-size: 1.1rem;
            display: flex;
            align-items: center;
            gap: 0.5rem;
        }
        .section-header .toggle {
            font-size: 1.2rem;
            transition: transform 0.3s;
            color: var(--text-gray);
            flex-shrink: 0;
        }
        .section-header .toggle.open { transform: rotate(180deg); }
        .section-body {
            max-height: 0;
            overflow: hidden;
            transition: max-height 0.4s ease;
        }
        .section-body.open { max-height: 5000px; }
        .section-content {
            padding: 0 1.5rem 1.5rem;
        }

        /* Typography inside sections */
        .section-content p { color: var(--text-gray); margin-bottom: 0.75rem; font-size: 0.9rem; }
        .section-content ul, .section-content ol {
            color: var(--text-gray);
            margin: 0 0 1rem 1.25rem;
            font-size: 0.9rem;
        }
        .section-content li { margin-bottom: 0.35rem; }
        .section-content h4 {
            color: var(--enrich-navy);
            font-size: 0.95rem;
            margin: 1.25rem 0 0.5rem;
        }

        /* Info boxes */
        .info-box {
            border-radius: 8px;
            padding: 1rem 1.25rem;
            margin: 1rem 0;
            font-size: 0.85rem;
        }
        .info-box.green { background: var(--green-light); border-left: 4px solid var(--green); }
        .info-box.amber { background: var(--amber-bg); border-left: 4px solid #F59E0B; }
        .info-box.red { background: var(--red-bg); border-left: 4px solid #EF4444; }
        .info-box.blue { background: #EFF6FF; border-left: 4px solid #3B82F6; }
        .info-box strong { display: block; margin-bottom: 0.3rem; }
        .info-box p { margin: 0; color: inherit; }

        /* Checklist */
        .checklist { list-style: none; margin: 0 0 1rem 0; padding: 0; }
        .checklist li {
            display: flex;
            align-items: flex-start;
            gap: 0.6rem;
            padding: 0.5rem 0.75rem;
            border-radius: 6px;
            margin-bottom: 0.3rem;
            font-size: 0.88rem;
            color: var(--text-gray);
            cursor: pointer;
            transition: background 0.2s;
        }
        .checklist li:hover { background: rgba(0,0,0,0.02); }
        .checklist li input[type="checkbox"] {
            width: 18px;
            height: 18px;
            margin-top: 2px;
            flex-shrink: 0;
            accent-color: var(--enrich-purple);
            cursor: pointer;
        }
        .checklist li.checked { color: var(--green); }
        .checklist li.checked span { text-decoration: line-through; opacity: 0.7; }

        .checklist-progress {
            background: var(--light-gray);
            border-radius: 20px;
            height: 8px;
            margin: 0.5rem 0 1rem;
            overflow: hidden;
        }
        .checklist-progress-bar {
            height: 100%;
            background: var(--enrich-purple);
            border-radius: 20px;
            transition: width 0.3s;
        }
        .checklist-label {
            font-size: 0.75rem;
            color: var(--text-gray);
            font-weight: 600;
        }

        /* Tables */
        .dose-table {
            width: 100%;
            border-collapse: collapse;
            margin: 1rem 0;
            font-size: 0.85rem;
        }
        .dose-table th {
            background: var(--enrich-navy);
            color: white;
            padding: 0.65rem 0.75rem;
            text-align: left;
            font-weight: 600;
            font-size: 0.8rem;
        }
        .dose-table td {
            padding: 0.6rem 0.75rem;
            border-bottom: 1px solid var(--light-gray);
        }
        .dose-table tr:hover td { background: rgba(139,42,125,0.04); }
        .dose-table tr:nth-child(even) td { background: var(--off-white); }
        .dose-table tr:nth-child(even):hover td { background: rgba(139,42,125,0.06); }
        .dose-table .highlight td { background: var(--light-purple); font-weight: 600; }

        /* Monitoring table */
        .monitor-table {
            width: 100%;
            border-collapse: collapse;
            margin: 1rem 0;
            font-size: 0.84rem;
        }
        .monitor-table th {
            background: var(--enrich-navy);
            color: white;
            padding: 0.6rem 0.75rem;
            text-align: left;
            font-weight: 600;
            font-size: 0.78rem;
        }
        .monitor-table td {
            padding: 0.6rem 0.75rem;
            border-bottom: 1px solid var(--light-gray);
            vertical-align: top;
        }
        .monitor-table .level { font-weight: 700; white-space: nowrap; }
        .monitor-table .level-warn { color: #D97706; }
        .monitor-table .level-danger { color: #DC2626; }

        /* Decision flowchart */
        .flow-step {
            display: flex;
            gap: 1rem;
            margin-bottom: 0.75rem;
            align-items: flex-start;
        }
        .flow-num {
            width: 32px;
            height: 32px;
            border-radius: 50%;
            background: var(--enrich-purple);
            color: white;
            display: flex;
            align-items: center;
            justify-content: center;
            font-weight: 700;
            font-size: 0.85rem;
            flex-shrink: 0;
        }
        .flow-content {
            flex: 1;
            padding-top: 4px;
            font-size: 0.9rem;
            color: var(--text-gray);
        }
        .flow-content strong { color: var(--enrich-navy); }
        .flow-connector {
            width: 2px;
            height: 16px;
            background: var(--light-gray);
            margin-left: 15px;
        }

        /* Route selector (interactive) */
        .route-cards {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(220px, 1fr));
            gap: 1rem;
            margin: 1rem 0;
        }
        .route-card {
            border: 2px solid var(--light-gray);
            border-radius: 10px;
            padding: 1.25rem;
            cursor: pointer;
            transition: all 0.2s;
            text-align: center;
        }
        .route-card:hover { border-color: var(--enrich-purple); }
        .route-card.selected {
            border-color: var(--enrich-purple);
            background: var(--light-purple);
            box-shadow: 0 0 0 3px rgba(139,42,125,0.15);
        }
        .route-card .icon { font-size: 2rem; margin-bottom: 0.5rem; }
        .route-card h4 { font-size: 0.95rem; color: var(--enrich-navy); margin-bottom: 0.3rem; }
        .route-card p { font-size: 0.8rem; color: var(--text-gray); margin: 0; }
        .route-card .tag {
            display: inline-block;
            padding: 0.15rem 0.5rem;
            border-radius: 12px;
            font-size: 0.7rem;
            font-weight: 600;
            margin-top: 0.5rem;
        }
        .tag-green { background: var(--green-light); color: var(--green); }
        .tag-blue { background: var(--blue-light); color: var(--blue-accent); }
        .tag-amber { background: var(--amber-light); color: var(--amber); }

        .route-detail {
            display: none;
            animation: fadeIn 0.3s ease;
        }
        .route-detail.visible { display: block; }

        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(8px); }
            to { opacity: 1; transform: translateY(0); }
        }

        /* Dose calculator */
        .calc-row {
            display: flex;
            gap: 1rem;
            align-items: center;
            flex-wrap: wrap;
            margin: 1rem 0;
        }
        .calc-row label {
            font-size: 0.85rem;
            font-weight: 600;
            color: var(--enrich-navy);
        }
        .calc-row select, .calc-row input {
            padding: 0.5rem 0.75rem;
            border: 1.5px solid var(--light-gray);
            border-radius: 6px;
            font-family: inherit;
            font-size: 0.9rem;
        }
        .calc-row select:focus, .calc-row input:focus {
            outline: none;
            border-color: var(--enrich-purple);
        }
        .calc-result {
            background: var(--light-purple);
            border-radius: 8px;
            padding: 1rem 1.25rem;
            margin: 0.75rem 0;
            font-size: 0.9rem;
        }
        .calc-result strong { color: var(--enrich-purple); }

        /* Footer */
        footer {
            background: var(--enrich-navy);
            color: white;
            padding: 2rem;
            margin-top: 2rem;
        }
        .footer-content {
            max-width: 1200px;
            margin: 0 auto;
            display: flex;
            justify-content: space-between;
            align-items: center;
            flex-wrap: wrap;
            gap: 1rem;
            font-size: 0.9rem;
        }
        .footer-content a { color: #93C5FD; }

        /* Print */
        @media print {
            header, nav, .nhs-banner, .quick-nav, .back-link, footer { display: none; }
            .section-body { max-height: none !important; }
            .section { box-shadow: none; border: 1px solid #ddd; break-inside: avoid; }
        }

        /* Mobile */
        @media (max-width: 768px) {
            .header-content { flex-direction: column; text-align: center; }
            .logo-section { flex-direction: column; gap: 0.5rem; }
            .logo-section img { height: 50px; }
            nav {
                width: 100%;
                overflow-x: auto;
                -webkit-overflow-scrolling: touch;
                scrollbar-width: none;
                justify-content: flex-start;
                padding-bottom: 5px;
            }
            nav::-webkit-scrollbar { display: none; }
            nav a {
                flex-shrink: 0;
                padding: 0.6rem 1rem;
                font-size: 0.85rem;
                min-height: 44px;
                display: flex;
                align-items: center;
            }
            main { padding: 1rem; }
            .page-hero { padding: 1.5rem; }
            .page-hero h2 { font-size: 1.3rem; }
            .page-hero .meta { flex-direction: column; gap: 0.25rem; }
            .route-cards { grid-template-columns: 1fr; }
            .dose-table, .monitor-table { font-size: 0.78rem; }
            .dose-table th, .dose-table td,
            .monitor-table th, .monitor-table td { padding: 0.4rem 0.5rem; }
            .calc-row { flex-direction: column; align-items: stretch; }
        }
    </style>
</head>
<body>

    <header>
        <div class="header-content">
            <a href="index.html" class="logo-section">
                <img src="EnRICH_Logo_solid.png" alt="EnRICH Logo">
                <div class="logo-text"><h1>EnRICH</h1><p>Enhanced Reviews in Care Homes</p></div>
            </a>
            <nav>
                <a href="index.html">Home</a>
                <a href="about.html">About EnRICH</a>
                <a href="services.html">Our Services</a>
                <a href="resources.html">Resources</a>
                <a href="team.html" class="pin-link">&#x1F512; Meet the Team</a>
                <a href="referral.html" class="pin-link">&#x1F512; Make a Referral</a>
                <a href="staff-portal.html" class="active pin-link">&#x1F512; Staff Portal</a>
            </nav>
        </div>
    </header>
    <div class="nhs-banner">A service provided by <strong>Cambridge University Hospitals NHS Foundation Trust</strong> &amp; <strong>Cambridgeshire &amp; Peterborough NHS Foundation Trust</strong></div>

    <main>
        <a href="portal-policies.html" class="back-link">&larr; Back to Policies &amp; Guidelines</a>

        <!-- HERO -->
        <div class="page-hero">
            <h2>&#x2764;&#xFE0F; Heart Failure Diuretic Management</h2>
            <p class="subtitle">Guidelines for the Administration of IV and SC Diuretics for Heart Failure Patients in the Community Setting</p>
            <div class="meta">
                <span>&#x1F3E5; CUH Virtual Ward &mdash; Division C</span>
                <span>&#x1F4C4; Version 2 &bull; October 2025</span>
                <span>&#x1F465; Butler, Ford &amp; Bines</span>
            </div>
        </div>

        <!-- DRAFT NOTICE -->
        <div class="draft-banner">
            <div class="icon">&#9888;&#xFE0F;</div>
            <div>
                <p><strong>Clinical Guideline &mdash; For Use by Trained Healthcare Professionals</strong></p>
                <p>This tool summarises the CUH guideline for parenteral diuretics in heart failure. It does not replace clinical judgement. Always discuss with a consultant or senior clinical team member when uncertain.</p>
            </div>
        </div>

        <!-- QUICK NAV -->
        <div class="quick-nav">
            <a href="#scope">&#x1F4CB; Scope</a>
            <a href="#selection">&#x2705; Patient Selection</a>
            <a href="#assessment">&#x1F50D; Assessment</a>
            <a href="#route">&#x1F48A; Choose Route</a>
            <a href="#monitoring">&#x1F4CA; Monitoring</a>
            <a href="#escalation">&#x26A0;&#xFE0F; Escalation</a>
            <a href="#discharge">&#x1F3E0; Discharge</a>
        </div>


        <!-- ============================================================ -->
        <!-- SECTION 1: SCOPE -->
        <!-- ============================================================ -->
        <div class="section" id="scope">
            <div class="section-header" onclick="toggleSection(this)">
                <h3>&#x1F4CB; Scope &amp; Purpose</h3>
                <span class="toggle open">&#x25BC;</span>
            </div>
            <div class="section-body open">
                <div class="section-content">
                    <p>These guidelines facilitate the administration of hospital-initiated diuretic therapy in patients' own homes under the management of the <strong> EnRICH Team or Virtual Ward at Cambridge University Hospitals NHS Foundation Trust</strong>.</p>

                    <h4>This protocol offers three treatment options:</h4>
                    <ol>
                        <li><strong>Oral metolazone</strong> &mdash; first-line choice due to ease of administration and efficacy</li>
                        <li><strong>Intravenous (IV) furosemide</strong> &mdash; for patients requiring parenteral diuresis</li>
                        <li><strong>Subcutaneous (SC) furosemide</strong> &mdash; anticipated for patients in their last days to weeks of life</li>
                    </ol>

                    <div class="info-box green">
                        <strong>&#x2705; Service aims</strong>
                        <p>Reduce hospital admissions for decompensated heart failure, facilitate earlier discharge, reduce hospital-related complications (deconditioning, falls, delirium, hospital-acquired infection), and avoid ED attendances.</p>
                    </div>
                </div>
            </div>
        </div>


        <!-- ============================================================ -->
        <!-- SECTION 2: PATIENT SELECTION -->
        <!-- ============================================================ -->
        <div class="section" id="selection">
            <div class="section-header" onclick="toggleSection(this)">
                <h3>&#x2705; Patient Selection</h3>
                <span class="toggle">&#x25BC;</span>
            </div>
            <div class="section-body">
                <div class="section-content">

                    <h4>Inclusion Criteria</h4>
                    <p class="checklist-label" id="inclusion-label">0 of 8 confirmed</p>
                    <div class="checklist-progress"><div class="checklist-progress-bar" id="inclusion-bar" style="width:0%"></div></div>
                    <ul class="checklist" id="inclusion-checklist">
                        <li onclick="toggleCheck(this, 'inclusion')"><input type="checkbox"><span>Accepted under the Virtual Ward for ongoing management</span></li>
                        <li onclick="toggleCheck(this, 'inclusion')"><input type="checkbox"><span>Heart failure confirmed as cause of symptoms (no reversible causes identified)</span></li>
                        <li onclick="toggleCheck(this, 'inclusion')"><input type="checkbox"><span>Fluid retention: peripheral oedema above the knee and/or weight gain &gt;3kg above dry weight</span></li>
                        <li onclick="toggleCheck(this, 'inclusion')"><input type="checkbox"><span>Failure to relieve fluid overload by lifestyle measures including fluid restriction</span></li>
                        <li onclick="toggleCheck(this, 'inclusion')"><input type="checkbox"><span>Considered bumetanide switch and thiazide addition (bumetanide 1mg &#x2248; furosemide 40mg)</span></li>
                        <li onclick="toggleCheck(this, 'inclusion')"><input type="checkbox"><span>Sufficient and appropriate social/family/carer support</span></li>
                        <li onclick="toggleCheck(this, 'inclusion')"><input type="checkbox"><span>Patient able to give informed consent to diuretic therapy at home</span></li>
                        <li onclick="toggleCheck(this, 'inclusion')"><input type="checkbox"><span>Patient able to weigh themselves (or be weighed) and take daily observations (HR/BP/SpO2)</span></li>
                    </ul>

                    <h4>Exclusion Criteria</h4>
                    <div class="info-box red">
                        <strong>&#x1F6D1; Do not proceed if any of the following apply:</strong>
                        <p></p>
                    </div>
                    <ul>
                        <li><strong>Symptomatic hypotension</strong> &mdash; first consider reduction or withdrawal of antihypertensives (e.g. amlodipine). Avoid abrupt withdrawal of beta-blockers (risk of rebound tachycardia).</li>
                        <li><strong>Insufficient carer support</strong></li>
                        <li><strong>Pulmonary oedema with uncontrolled respiratory distress</strong> and the patient is a candidate for escalation to intensive heart failure management under Cardiology. If expected as part of ongoing treatment, consider palliative symptom control (e.g. opioids).</li>
                    </ul>
                </div>
            </div>
        </div>


        <!-- ============================================================ -->
        <!-- SECTION 3: INITIAL ASSESSMENT -->
        <!-- ============================================================ -->
        <div class="section" id="assessment">
            <div class="section-header" onclick="toggleSection(this)">
                <h3>&#x1F50D; Initial Assessment &amp; Onboarding</h3>
                <span class="toggle">&#x25BC;</span>
            </div>
            <div class="section-body">
                <div class="section-content">

                    <p class="checklist-label" id="assessment-label">0 of 10 completed</p>
                    <div class="checklist-progress"><div class="checklist-progress-bar" id="assessment-bar" style="width:0%"></div></div>
                    <ul class="checklist" id="assessment-checklist">
                        <li onclick="toggleCheck(this, 'assessment')"><input type="checkbox"><span>On VW EPIC referral, request symptom monitoring: SOB, PND, orthopnoea, leg swelling</span></li>
                        <li onclick="toggleCheck(this, 'assessment')"><input type="checkbox"><span>Document BP, HR, weight and target weight (EPIC synopsis useful)</span></li>
                        <li onclick="toggleCheck(this, 'assessment')"><input type="checkbox"><span>Advise patient on fluid intake recording and any fluid restriction</span></li>
                        <li onclick="toggleCheck(this, 'assessment')"><input type="checkbox"><span>Obtain baseline U&amp;Es</span></li>
                        <li onclick="toggleCheck(this, 'assessment')"><input type="checkbox"><span>Determine treatment route: metolazone, IV furosemide, or SC furosemide</span></li>
                        <li onclick="toggleCheck(this, 'assessment')"><input type="checkbox"><span>Review infusion site if in-situ; check for signs of infection</span></li>
                        <li onclick="toggleCheck(this, 'assessment')"><input type="checkbox"><span>Advise patient/carer on medication changes; no oral diuretics on day of IV administration</span></li>
                        <li onclick="toggleCheck(this, 'assessment')"><input type="checkbox"><span>Consider toileting needs &mdash; commode or short-term catheter if mobility is an issue</span></li>
                        <li onclick="toggleCheck(this, 'assessment')"><input type="checkbox"><span>Establish Treatment Escalation Plan (ReSPECT form) &mdash; ensure printed, signed copy with patient</span></li>
                        <li onclick="toggleCheck(this, 'assessment')"><input type="checkbox"><span>Send discharge letter and onboarding documentation to GP immediately</span></li>
                    </ul>
                </div>
            </div>
        </div>


        <!-- ============================================================ -->
        <!-- SECTION 4: ROUTE OF ADMINISTRATION -->
        <!-- ============================================================ -->
        <div class="section" id="route">
            <div class="section-header" onclick="toggleSection(this)">
                <h3>&#x1F48A; Choose Route of Administration</h3>
                <span class="toggle">&#x25BC;</span>
            </div>
            <div class="section-body">
                <div class="section-content">
                    <p>Select a treatment route based on clinical assessment, patient preference, device availability, and goals of care:</p>

                    <div class="route-cards">
                        <div class="route-card" onclick="selectRoute('metolazone')">
                            <div class="icon">&#x1F48A;</div>
                            <h4>Oral Metolazone</h4>
                            <p>First-line choice for ease of administration</p>
                            <span class="tag tag-green">FIRST LINE</span>
                        </div>
                        <div class="route-card" onclick="selectRoute('iv')">
                            <div class="icon">&#x1F489;</div>
                            <h4>IV Furosemide</h4>
                            <p>Parenteral diuresis for refractory fluid overload</p>
                            <span class="tag tag-blue">SECOND LINE</span>
                        </div>
                        <div class="route-card" onclick="selectRoute('sc')">
                            <div class="icon">&#x1F3E5;</div>
                            <h4>SC Furosemide</h4>
                            <p>End of life symptom control; last days to weeks</p>
                            <span class="tag tag-amber">PALLIATIVE</span>
                        </div>
                    </div>

                    <!-- METOLAZONE DETAIL -->
                    <div class="route-detail" id="route-metolazone">
                        <h4>&#x1F48A; Oral Metolazone Administration</h4>

                        <div class="info-box blue">
                            <strong>Patient Information Leaflet</strong>
                            <p>Provide the CUH PIL: Thiazide diuretic (water tablet): metolazone</p>
                        </div>

                        <div class="flow-step"><div class="flow-num">1</div><div class="flow-content"><strong>Prescribe licensed metolazone (Xaqua&reg;)</strong> &mdash; refer to prescribing support document for additional information.</div></div>
                        <div class="flow-connector"></div>
                        <div class="flow-step"><div class="flow-num">2</div><div class="flow-content"><strong>Give stat dose: Metolazone 2.5mg</strong></div></div>
                        <div class="flow-connector"></div>
                        <div class="flow-step"><div class="flow-num">3</div><div class="flow-content"><strong>Daily monitoring</strong> as per monitoring guidance below.</div></div>
                        <div class="flow-connector"></div>
                        <div class="flow-step"><div class="flow-num">4</div><div class="flow-content"><strong>Review symptoms, signs and weight loss</strong> to guide subsequent doses. Metolazone is often required <strong>2&ndash;3 times per week</strong>.</div></div>
                        <div class="flow-connector"></div>
                        <div class="flow-step"><div class="flow-num">5</div><div class="flow-content"><strong>U&amp;E monitoring:</strong> minimum twice weekly (may be less frequent than IV route).</div></div>

                        <div class="info-box green">
                            <strong>&#x2705; On completion</strong>
                            <p>Optimise oral diuretics, review other HF medications (ACEi/ARB, SGLT2i, MRA) with GP advice on up-titration, send comprehensive discharge letter with current weight, target weight, and diuretic plan if weight increases.</p>
                        </div>
                    </div>

                    <!-- IV FUROSEMIDE DETAIL -->
                    <div class="route-detail" id="route-iv">
                        <h4>&#x1F489; IV Furosemide Administration</h4>

                        <div class="info-box amber">
                            <strong>&#x26A0;&#xFE0F; Key prescribing points</strong>
                            <p>Maximum rate: <strong>4mg/min</strong>. Commence no later than <strong>4pm</strong> to avoid excess overnight toileting. Dilute in NaCl 0.9% if necessary. Glucose solutions are unsuitable. Oral diuretics have ~50&ndash;60% bioavailability vs 100% IV.</p>
                        </div>

                        <h4>Dose Conversion: Oral &rarr; IV</h4>
                        <p>Start at equivalent dose or increase by one increment if clinically appropriate:</p>

                        <table class="dose-table">
                            <thead>
                                <tr>
                                    <th>PO Furosemide</th>
                                    <th>PO Bumetanide</th>
                                    <th>IV Furosemide</th>
                                    <th>Infusion Time</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr><td>40mg</td><td>1mg</td><td>40mg</td><td>Slow IV push over 10 mins</td></tr>
                                <tr><td>80mg</td><td>2mg</td><td>80mg</td><td>20 mins</td></tr>
                                <tr><td>120mg</td><td>3mg</td><td>120mg</td><td>30 mins</td></tr>
                                <tr><td>160mg</td><td>4mg</td><td>160mg</td><td>40 mins</td></tr>
                                <tr><td>200mg</td><td>5mg</td><td>200mg</td><td>50 mins</td></tr>
                                <tr><td>240mg</td><td>6mg</td><td>240mg</td><td>60 mins</td></tr>
                            </tbody>
                        </table>

                        <!-- DOSE CALCULATOR -->
                        <h4>&#x1F5A9; Quick Dose Calculator</h4>
                        <div class="calc-row">
                            <label for="current-oral">Current oral diuretic:</label>
                            <select id="current-oral" onchange="calculateDose()">
                                <option value="">-- Select --</option>
                                <option value="furo-40">Furosemide 40mg</option>
                                <option value="furo-80">Furosemide 80mg</option>
                                <option value="furo-120">Furosemide 120mg</option>
                                <option value="furo-160">Furosemide 160mg</option>
                                <option value="furo-200">Furosemide 200mg</option>
                                <option value="furo-240">Furosemide 240mg</option>
                                <option value="bumet-1">Bumetanide 1mg</option>
                                <option value="bumet-2">Bumetanide 2mg</option>
                                <option value="bumet-3">Bumetanide 3mg</option>
                                <option value="bumet-4">Bumetanide 4mg</option>
                                <option value="bumet-5">Bumetanide 5mg</option>
                                <option value="bumet-6">Bumetanide 6mg</option>
                            </select>
                        </div>
                        <div class="calc-result" id="dose-result" style="display:none;"></div>

                        <h4>Failure to respond</h4>
                        <div class="flow-step"><div class="flow-num">1</div><div class="flow-content"><strong>Increase loop diuretic</strong> by 40mg furosemide increments (max 240mg).</div></div>
                        <div class="flow-connector"></div>
                        <div class="flow-step"><div class="flow-num">2</div><div class="flow-content"><strong>Consider adding metolazone</strong> &mdash; this will reduce the ongoing requirement for IV diuretic therapy.</div></div>
                        <div class="flow-connector"></div>
                        <div class="flow-step"><div class="flow-num">3</div><div class="flow-content"><strong>If no response within 72 hours</strong> (or agreed timeframe) &mdash; discuss with patient regarding wishes and goals of care. Consider switching focus to comfort and dignity vs. further hospital-based management.</div></div>

                        <div class="info-box green">
                            <strong>&#x2705; On completion</strong>
                            <p>Convert to appropriate oral dose. Review all HF medications with GP advice on continuation and up-titration (ACEi/ARB, SGLT2i, MRA). Send comprehensive discharge letter with current weight, target weight, U&amp;E follow-up plan (usually within 1 week), and organised follow-up with local heart failure teams.</p>
                        </div>
                    </div>

                    <!-- SC FUROSEMIDE DETAIL -->
                    <div class="route-detail" id="route-sc">
                        <h4>&#x1F3E5; Subcutaneous Furosemide &mdash; End of Life</h4>

                        <div class="info-box red">
                            <strong>&#x26A0;&#xFE0F; Unlicensed use</strong>
                            <p>SC furosemide is unlicensed in the UK but has been used with success (Dickman &amp; Schneider 2016). For end-stage heart failure patients requiring parenteral diuresis for symptom control. Initiate alongside symptomatic management of dyspnoea (opiates and/or benzodiazepines) as necessary.</p>
                        </div>

                        <h4>Inclusion criteria (SC route)</h4>
                        <ul>
                            <li>End-stage heart failure, unresponsive or unable to tolerate higher-dose oral or IV diuretics</li>
                            <li>Wish to avoid hospital admission; IV diuretics in the community cannot be facilitated</li>
                            <li>Last days of life requiring ongoing diuretics for symptom relief</li>
                        </ul>

                        <h4>Exclusion criteria (SC route)</h4>
                        <ul>
                            <li>No identifiable symptomatic benefit from high-dose IV or SC therapy</li>
                            <li>Severe site reaction to SC administration</li>
                        </ul>

                        <h4>Dosing</h4>
                        <div class="info-box blue">
                            <strong>SC dosing is a 1:1 conversion from oral dose</strong>
                            <p>e.g. 120mg furosemide orally daily = 120mg/24h via syringe pump. Note: oral bioavailability is ~60&ndash;70%, so this represents a dose increase. Use previous oral 24h requirement as starting dose and titrate to response. Convert bumetanide to furosemide equivalence first (bumetanide 1mg &#x2248; furosemide 40mg).</p>
                        </div>

                        <h4>Syringe driver practical points</h4>
                        <ul>
                            <li>Furosemide must be used as a <strong>solitary agent</strong> &mdash; do not mix with other medications</li>
                            <li>Concentration: 10mg/1ml ampoules</li>
                            <li>T34&trade; syringe pump max capacity: 17ml (&#x2248; 170mg/24h per pump)</li>
                            <li>Higher doses: use two pumps or 12-hourly administration (e.g. 2 &times; 120mg)</li>
                            <li>May dilute with NaCl 0.9% if syringe capacity allows, or administer undiluted</li>
                            <li>Protect from light; discard if solution is yellow (degradation)</li>
                        </ul>

                        <h4>Infusion sites</h4>
                        <ul>
                            <li>Upper chest or upper anterior arms</li>
                            <li>Avoid: bony prominences, damaged tissue, oedematous areas, tattoos (may mask reactions)</li>
                            <li>Note: very poor peripheral perfusion in terminal stage may limit SC absorption</li>
                        </ul>

                        <h4>End of life monitoring</h4>
                        <ul>
                            <li>Daily symptom monitoring &mdash; focus on comfort</li>
                            <li>Daily infusion site inspection (pain, itching, redness may require re-siting or cessation)</li>
                            <li>U&amp;E monitoring as advised by VW consultant; <strong>not appropriate in the last few days of life</strong></li>
                            <li>Weight monitoring also <strong>not appropriate in the last few days of life</strong></li>
                        </ul>

                        <h4>Contraindications &amp; precautions</h4>
                        <p>For patients in the final days of life, the prescriber must consider these but they may not necessarily deter use if the dose is carefully titrated:</p>
                        <ul>
                            <li>Anuria</li>
                            <li>Comatose/pre-comatose states with hepatic cirrhosis</li>
                            <li>CrCl &lt;30ml/min per 1.73m&sup2;</li>
                            <li>Dehydration, hypovolaemia, or hyponatraemia</li>
                            <li>Drug-induced renal failure</li>
                            <li>Hypersensitivity to sulphonamides</li>
                        </ul>
                    </div>

                </div>
            </div>
        </div>


        <!-- ============================================================ -->
        <!-- SECTION 5: MONITORING -->
        <!-- ============================================================ -->
        <div class="section" id="monitoring">
            <div class="section-header" onclick="toggleSection(this)">
                <h3>&#x1F4CA; Ongoing Monitoring</h3>
                <span class="toggle">&#x25BC;</span>
            </div>
            <div class="section-body">
                <div class="section-content">

                    <h4>Daily monitoring</h4>
                    <ul>
                        <li>Heart failure symptoms: SOB, orthopnoea, PND, exercise tolerance, change in swelling, dizziness on standing</li>
                        <li>Blood pressure, heart rate, weight, fluid balance</li>
                        <li>Infusion site review (if applicable)</li>
                        <li>If symptomatic low BP: stop or reduce other antihypertensives</li>
                        <li><strong>Target weight loss: ~500g/day</strong></li>
                    </ul>

                    <h4>Renal function &amp; electrolyte monitoring</h4>
                    <p>U&amp;Es every 48&ndash;72 hours (decided by specialist). Metolazone: minimum twice weekly.</p>

                    <table class="monitor-table">
                        <thead>
                            <tr>
                                <th>Parameter</th>
                                <th>Level</th>
                                <th>Action Required</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td rowspan="3"><strong>Potassium</strong></td>
                                <td class="level">&lt;3.5 mmol/L</td>
                                <td>Short course of oral K+ supplements and dietary advice. If continues to reduce, consider an MRA.</td>
                            </tr>
                            <tr>
                                <td class="level level-warn">&gt;5.5&ndash;&lt;6.0 mmol/L</td>
                                <td>Stop K+ supplements, K+-sparing diuretics. Consider reducing/stopping ACEi, ARBs, MRAs, or sacubitril/valsartan. Consider haemolysis if other results stable &mdash; repeat.</td>
                            </tr>
                            <tr>
                                <td class="level level-danger">&gt;6.0 mmol/L</td>
                                <td><strong>URGENT:</strong> Repeat sampling and ECG. Discuss with senior clinical team. Refer to MERLIN hyperkalaemia guideline.</td>
                            </tr>
                            <tr>
                                <td rowspan="2"><strong>Sodium</strong></td>
                                <td class="level level-danger">&lt;125 mmol/L</td>
                                <td><strong>If symptomatic:</strong> urgent patient assessment, discuss with senior clinical team.<br><strong>If asymptomatic:</strong> consider stopping/holding medications known to reduce sodium.</td>
                            </tr>
                            <tr>
                                <td class="level level-warn">125&ndash;127 mmol/L</td>
                                <td>Consider stopping medications known to reduce sodium (MRAs, ACEIs, antidepressants, PPIs). Increase U&amp;E monitoring frequency.</td>
                            </tr>
                            <tr>
                                <td><strong>Creatinine</strong></td>
                                <td class="level level-danger">Increase &gt;50% of baseline or &gt;300&mu;mol/L</td>
                                <td>Reduce/stop nephrotoxic medications. If creatinine continues to increase: urgent patient assessment and discussion with senior clinical team.</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </div>
        </div>


        <!-- ============================================================ -->
        <!-- SECTION 6: ESCALATION -->
        <!-- ============================================================ -->
        <div class="section" id="escalation">
            <div class="section-header" onclick="toggleSection(this)">
                <h3>&#x26A0;&#xFE0F; Escalation Pathway</h3>
                <span class="toggle">&#x25BC;</span>
            </div>
            <div class="section-body">
                <div class="section-content">

                    <div class="info-box red">
                        <strong>&#x1F6A8; Escalate immediately if:</strong>
                        <p>K+ &gt;6.0 mmol/L &bull; Symptomatic Na+ &lt;125 mmol/L &bull; Creatinine rising &gt;50% above baseline &bull; Uncontrolled respiratory distress &bull; Symptomatic hypotension unresponsive to antihypertensive withdrawal</p>
                    </div>

                    <h4>Stepwise escalation for IV diuretics</h4>
                    <div class="flow-step"><div class="flow-num">1</div><div class="flow-content"><strong>Increase IV furosemide</strong> by 40mg increments (maximum 240mg).</div></div>
                    <div class="flow-connector"></div>
                    <div class="flow-step"><div class="flow-num">2</div><div class="flow-content"><strong>Add metolazone</strong> to reduce ongoing IV requirement.</div></div>
                    <div class="flow-connector"></div>
                    <div class="flow-step"><div class="flow-num">3</div><div class="flow-content"><strong>No response within 72 hours:</strong> discuss with patient regarding wishes and goals of care.</div></div>
                    <div class="flow-connector"></div>
                    <div class="flow-step"><div class="flow-num">4</div><div class="flow-content">Consider: <strong>comfort-focused care at home</strong> vs. <strong>further hospital-based management</strong>, guided by patient's ReSPECT form and advance care plan.</div></div>

                    <div class="info-box amber">
                        <strong>&#x260E;&#xFE0F; Key contacts</strong>
                        <p>CUH EnRICH Team (via email) & Virtual Ward (24h): <strong>01223 806806</strong></p>
                    </div>
                </div>
            </div>
        </div>


        <!-- ============================================================ -->
        <!-- SECTION 7: DISCHARGE -->
        <!-- ============================================================ -->
        <div class="section" id="discharge">
            <div class="section-header" onclick="toggleSection(this)">
                <h3>&#x1F3E0; Discharge from Virtual Ward</h3>
                <span class="toggle">&#x25BC;</span>
            </div>
            <div class="section-body">
                <div class="section-content">

                    <h4>Discharge checklist</h4>
                    <p class="checklist-label" id="discharge-label">0 of 7 completed</p>
                    <div class="checklist-progress"><div class="checklist-progress-bar" id="discharge-bar" style="width:0%"></div></div>
                    <ul class="checklist" id="discharge-checklist">
                        <li onclick="toggleCheck(this, 'discharge')"><input type="checkbox"><span>IV/SC diuretics converted to appropriate oral dose</span></li>
                        <li onclick="toggleCheck(this, 'discharge')"><input type="checkbox"><span>Other HF medications reviewed with GP advice on up-titration (ACEi/ARB, SGLT2i, MRA)</span></li>
                        <li onclick="toggleCheck(this, 'discharge')"><input type="checkbox"><span>Current weight and target weight documented</span></li>
                        <li onclick="toggleCheck(this, 'discharge')"><input type="checkbox"><span>Comprehensive discharge letter sent to GP</span></li>
                        <li onclick="toggleCheck(this, 'discharge')"><input type="checkbox"><span>U&amp;E follow-up plan documented (usually within 1&ndash;2 weeks)</span></li>
                        <li onclick="toggleCheck(this, 'discharge')"><input type="checkbox"><span>Follow-up with local heart failure team arranged</span></li>
                        <li onclick="toggleCheck(this, 'discharge')"><input type="checkbox"><span>Patient provided with heart failure self-management plan including diuretic plan if weight increases</span></li>
                    </ul>
                </div>
            </div>
        </div>


        <!-- ============================================================ -->
        <!-- REFERENCE -->
        <!-- ============================================================ -->
        <div class="section" id="references">
            <div class="section-header" onclick="toggleSection(this)">
                <h3>&#x1F4DA; References &amp; Resources</h3>
                <span class="toggle">&#x25BC;</span>
            </div>
            <div class="section-body">
                <div class="section-content">
                    <ul>
                        <li>Verma AK, da Silva JH, Kuhl DR. Diuretic effects of subcutaneous furosemide in human volunteers: a randomized pilot study. <em>Ann Pharmacother</em> 2004;38:544&ndash;9.</li>
                        <li>Zacharias H, Raw J, Nunn A, et al. Is there a role for subcutaneous furosemide in the community and hospice management of end-stage heart failure? <em>Palliat Med</em> 2011;25:658&ndash;63.</li>
                        <li>Dickman A, Schneider J. <em>The Syringe Driver: Continuous Subcutaneous Infusions in Palliative Care</em>. 4th ed. Oxford University Press, 2016.</li>
                        <li>Furosemide 20mg/2ml Solution for Injection &mdash; Summary of Product Characteristics (SmPC) &mdash; emc</li>
                        <li>Metolazone (Xaqua&reg;) prescribing support document</li>
                    </ul>
                    <div class="info-box blue">
                        <strong>Source document</strong>
                        <p>CUH Virtual Ward, Division C &mdash; Guideline for the Administration of Intravenous and Subcutaneous Diuretics for Heart Failure Patients in the Community Setting. Version 2, October 2025. Authors: Dr Matthew Butler, Dr Joanna Ford, Ms Emma Bines.</p>
                    </div>
                </div>
            </div>
        </div>

    </main>

    <footer>
        <div class="footer-content">
            <p>&copy; 2026 EnRICH &mdash; Enhanced Reviews in Care Homes<br>Cambridge University Hospitals NHS Foundation Trust</p>
            <p><a href="portal-policies.html">Policies &amp; Guidelines</a> | <a href="staff-portal.html">Staff Portal</a></p>
        </div>
    </footer>

    <script>
        // ===== AUTH CHECK =====
        (function() {
            try {
                if (sessionStorage.getItem('enrich_auth') !== 'true') {
                    window.location.href = 'staff-portal.html';
                }
            } catch(e) {
                window.location.href = 'staff-portal.html';
            }
        })();

        // ===== SECTION TOGGLE =====
        function toggleSection(header) {
            const body = header.nextElementSibling;
            const toggle = header.querySelector('.toggle');
            body.classList.toggle('open');
            toggle.classList.toggle('open');
        }

        // ===== CHECKLIST =====
        function toggleCheck(li, group) {
            const cb = li.querySelector('input[type="checkbox"]');
            cb.checked = !cb.checked;
            li.classList.toggle('checked', cb.checked);
            updateProgress(group);
        }

        function updateProgress(group) {
            const checklist = document.getElementById(group + '-checklist');
            const items = checklist.querySelectorAll('input[type="checkbox"]');
            const checked = checklist.querySelectorAll('input[type="checkbox"]:checked').length;
            const total = items.length;

            document.getElementById(group + '-bar').style.width = (checked / total * 100) + '%';
            document.getElementById(group + '-label').textContent = checked + ' of ' + total + (group === 'inclusion' ? ' confirmed' : ' completed');
        }

        // ===== ROUTE SELECTOR =====
        function selectRoute(route) {
            // Toggle cards
            document.querySelectorAll('.route-card').forEach(c => c.classList.remove('selected'));
            event.currentTarget.classList.add('selected');

            // Toggle detail panels
            document.querySelectorAll('.route-detail').forEach(d => d.classList.remove('visible'));
            const detail = document.getElementById('route-' + route);
            if (detail) detail.classList.add('visible');
        }

        // ===== DOSE CALCULATOR =====
        function calculateDose() {
            const sel = document.getElementById('current-oral').value;
            const result = document.getElementById('dose-result');
            if (!sel) { result.style.display = 'none'; return; }

            const doseMap = {
                'furo-40': { iv: 40, time: 'slow IV push over 10 minutes', oral: 'Furosemide 40mg' },
                'furo-80': { iv: 80, time: '20 minutes', oral: 'Furosemide 80mg' },
                'furo-120': { iv: 120, time: '30 minutes', oral: 'Furosemide 120mg' },
                'furo-160': { iv: 160, time: '40 minutes', oral: 'Furosemide 160mg' },
                'furo-200': { iv: 200, time: '50 minutes', oral: 'Furosemide 200mg' },
                'furo-240': { iv: 240, time: '60 minutes', oral: 'Furosemide 240mg' },
                'bumet-1': { iv: 40, time: 'slow IV push over 10 minutes', oral: 'Bumetanide 1mg' },
                'bumet-2': { iv: 80, time: '20 minutes', oral: 'Bumetanide 2mg' },
                'bumet-3': { iv: 120, time: '30 minutes', oral: 'Bumetanide 3mg' },
                'bumet-4': { iv: 160, time: '40 minutes', oral: 'Bumetanide 4mg' },
                'bumet-5': { iv: 200, time: '50 minutes', oral: 'Bumetanide 5mg' },
                'bumet-6': { iv: 240, time: '60 minutes', oral: 'Bumetanide 6mg' },
            };

            const d = doseMap[sel];
            result.style.display = 'block';
            result.innerHTML = `
                <strong>${d.oral} &#x2192; IV Furosemide ${d.iv}mg</strong><br>
                Infusion time: ${d.time}<br>
                Max rate: 4mg/min &bull; Commence no later than 4pm<br>
                <span style="font-size: 0.8rem; color: var(--text-gray);">SC equivalent (end of life): ${d.iv}mg/24h via syringe pump (1:1 from oral dose, noting increased bioavailability)</span>
            `;
        }
    </script>
</body>
</html>
